Members of the ADAM family, including ADAM9, ADAM10, and ADAM17, mediate signaling pathways in gastrointestinal cancer formation,[47] Targeting ADAM10 and ADAM17 has demonstrated promising antitumor activity, as exemplified by compounds such as INCB3619 and INCB7839.[48] Among the three ADAMs, a direct interaction was observed only between NOTCH2 and ADAM10 in CRC. Here, ADAM17 is linked to colorectal carcinoma.